NEW YORK, June 1 /PRNewswire/ -- Pfizer Inc said today it will present
important data on cancer therapies and report progress across its oncology
pipeline at the 2006 American Society for Clinical Oncology (ASCO) meeting
in Atlanta, Georgia.
More than 100 studies will be presented on Pfizer medicines, with new
findings in breast, kidney, colorectal, gastrointestinal stromal tumor
(GIST), lung, thyroid, melanoma, ovarian, and neuroendocrine cancer
research. Following are key abstracts:
PRODUCT TIME DATA
SUTENT(R) June 3 SUTENT phase III results in
(sunitinib malate) 4:45pm - gastrointestinal stromal tumors
5:00pm
SUTENT(R) June 4 SUTENT phase II results in lung
(sunitinib malate) 8:35am - cancer
8:50am
SUTENT(R) June 4 phase III results of SUTENT
(sunitinib malate) 3:10pm - versus interferon-alpha as a
3:25pm first-line systemic therapy for
patients with advanced kidney
cancer
AROMASIN(R) June 5 Five year analysis of survival
(exemestane tablets) 11:30am - data
11:45am
CAMPTOSAR(R) June 5 CAMPTOSAR as a first-line
(irinotecan HCl 3:30pm - treatment for colorectal cancer
injection) 3:45pm
"The breadth and depth of data presentations at ASCO will underscore
the innovation behind Pfizer's oncology portfolio and our commitment to
meeting critical patient and physician needs," said Dr. John LaMattina,
president of Pfizer Global Research and Development. "Our team of
scientists is working hard to transform cancer into a disease patients live
with instead of die from."
On Sunday, June 4, Pfizer will host a press briefing that will present
new medical information on Pfizer cancer medicines and provide an overview
on the company's broad oncology pipeline. The briefing will be held at the
Westin Peachtree Plaza in Atlanta, Georgia, from 6:00 to 7:30 p.m.
SOURCE Pfizer Inc
 back to top
Related links:
http://www.pfizer.com
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiveror electronic darkroom, PC or
Macintosh, that can accept overheadtransmissions. To retrieve a
logo, please call 972-392-0888./ /Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Pfizer's press releases are available through PR Newswire's
Company News On-Call service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html/
CONTACT:
Betsy Raymond, +1-212-733-6572, or cell,
+1-860-501-3247
|
